Asia

lung
Favicon Fierce Pharma

ASCO: Merck, Kelun's sac-TMT combo beats Keytruda by 65% on PFS

Combining the TROP2 ADC with Keytruda cut the risk of progression or death by 65% versus Keytruda alone in first-line, PD-L1-positive NSCLC.
Angus Liu May 21, 2026 5:00pm
Takeda
Favicon Fierce Pharma

Takeda targets $1.3B in savings with new efficiency drive

Mar 25, 2026 10:44am
NVS
Favicon Fierce Pharma

Novartis pledges nearly $480M to bolster China production, R&D

Mar 23, 2026 10:35am
AstraZeneca
Favicon Fierce Pharma

AZ to build cell therapy supply hub, R&D center in Shanghai

Mar 19, 2026 10:20am
Sanofi
Favicon Fierce Pharma

Sanofi inks $1.5B deal for Sino Biopharm's novel asset

Mar 4, 2026 3:00am
Astellas
Favicon Fierce Pharma

Astellas lifts forecast as Vyloy surge counters trial miss

Feb 5, 2026 11:00am